Edward Kim, MD

Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.

Continuing discussion on the treatment of patients with EGFR-mutated NSCLC, Sandip P. Patel, MD, discusses the role of EGFR TKIs without chemotherapy.

Focusing on data from the FLAURA2 study, Erminia Massarelli, MD, PhD, MS, outlines the role of EGFR TKI plus chemotherapy for patients with EGFR-mutated NSCLC.

Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.

Karen M. Yun, MD, discusses the role for neoadjuvant chemoimmunotherapy in patients with resectable non–small cell lung cancer.

Ramya Muddasani, DO, MS, leads a discussion on the treatment of a patient with metastatic NSCLC with a KRAS G12C mutation, highlighting the utilization of sotorasib and the CodeBreaK 100 trial.

Sandip P. Patel, MD, reviews the case of a patient with PD-L1–negative NSCLC and discusses treatment practices.

Ramya Muddasani, DO, MS, presents the case of a patient with EGFR-mutated NSCLC following osimertinib treatment and shares insights gleaned from the INSIGHT 2 trial.

Initiating a conversation on patient cases, Karen Yun, MD, presents the profile of a patient with metastatic ROS1 fusion-positive non–small cell lung cancer.

Jyoti Malhotra, MD, MPH, reviews data from the phase III POSEIDON study evaluating durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for patients with metastatic NSCLC.

Amanda Herrmann, MD, discusses findings from the 5-year update from CheckMate-9LA investigating nivolumab, ipilimumab, and chemotherapy in patients with metastatic NSCLC.

Karen Yun, MD, opens the discussion by presenting data from the ALTA-1L and BRIGHTSTAR studies on advanced ALK-rearranged non–small cell lung cancer.

Erminia Massarelli, MD, PhD, MS, presents 5-year progression-free survival and safety data from the CROWN study comparing lorlatinib with crizotinib in treatment-naïve patients with advanced ALK+ NSCLC.

Edward Kim, MD, introduces a CancerNetwork® Face-Off program in which University of California San Diego and City of Hope will present clinical trial data and discuss treatment practices in non–small cell lung cancer (NSCLC).

Combined-modality approaches for the treatment of non-small-cell lung cancer (NSCLC), head and neck cancer, and esophageal cancer offer survival benefits by improving locoregional control and treating micrometastatic disease. The taxanes are active, tolerable drugs in these solid tumors and have radiation-sensitizing activity.